Omnicell (NASDAQ:OMCL - Free Report) had its price target boosted by Bank of America from $30.00 to $34.00 in a research note released on Friday morning,Benzinga reports. Bank of America currently has a neutral rating on the stock.
A number of other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. cut their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Wells Fargo & Company reiterated an "overweight" rating and issued a $37.00 price objective (up from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Benchmark cut their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Wall Street Zen raised Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, May 20th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Omnicell presently has a consensus rating of "Moderate Buy" and an average target price of $44.83.
View Our Latest Research Report on OMCL
Omnicell Stock Performance
NASDAQ OMCL traded down $0.24 during trading hours on Friday, reaching $29.37. The company's stock had a trading volume of 395,319 shares, compared to its average volume of 564,799. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The business has a 50-day simple moving average of $30.70 and a 200 day simple moving average of $38.41. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.75. The stock has a market cap of $1.38 billion, a PE ratio of 108.78, a PEG ratio of 7.53 and a beta of 0.78.
Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The business's revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $0.03 EPS. Equities research analysts predict that Omnicell will post 1.09 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Omnicell
A number of hedge funds and other institutional investors have recently modified their holdings of OMCL. Strs Ohio bought a new stake in shares of Omnicell during the 1st quarter worth about $5,635,000. Acadian Asset Management LLC bought a new stake in shares of Omnicell during the 1st quarter worth about $4,394,000. Intech Investment Management LLC raised its holdings in Omnicell by 75.6% during the first quarter. Intech Investment Management LLC now owns 230,171 shares of the company's stock worth $8,047,000 after purchasing an additional 99,104 shares in the last quarter. Jane Street Group LLC raised its holdings in Omnicell by 201.5% during the first quarter. Jane Street Group LLC now owns 163,664 shares of the company's stock worth $5,722,000 after purchasing an additional 109,382 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Omnicell by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company's stock worth $4,337,000 after purchasing an additional 4,866 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.
About Omnicell
(
Get Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Further Reading
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
